GLP- 1 Agonist Therapy Center

The relationship between GLP-1 therapies and atrial fibrillation is an emerging topic in diabetes care, raising an important question: could medications designed to protect the heart also influence its rhythm? Patients with diabetes already face a higher risk of atrial fibrillation, so understanding how these GLP-1 receptor agonists affect cardiac …

A proper baseline assessment for GLP-1 therapy has become a critical yet sometimes overlooked step in modern diabetes care. In fast-moving clinical environments, especially with the rise of telehealth, providers may feel pressure to initiate GLP-1 therapy quickly. However, skipping essential baseline evaluations can lead to missed risks, poor outcomes, …

GLP-1 therapies are becoming an important focus in peripheral artery disease, especially as clinicians look beyond glucose control to improve outcomes in high-risk patients. People with diabetes and peripheral artery disease often face a difficult path, marked by poor circulation, delayed wound healing, and a higher risk of amputation. While …

Disease progression in patients using GLP-1 therapies is becoming a critical topic as these medications continue to reshape diabetes care. While GLP-1 receptor agonists improve glycemic control and support weight loss, could they also be hiding deeper metabolic decline? Much like a polished surface that conceals underlying cracks, improved lab …

GLP-1 receptor agonists as adjunct therapy in type 1 diabetes are gaining attention as clinicians look for new ways to improve glycemic control. But is this approach a promising tool or a risky shortcut? As emerging evidence builds, providers must balance potential benefits with safety concerns and patient-specific factors. Table …

Telehealth prescribing of GLP-1 medications is rapidly reshaping how diabetes and weight management care is delivered. But as access expands, an important question emerges: who is truly managing patient care? Like a relay race without a clear handoff, patients often move between providers, platforms, and pharmacies without consistent oversight. As …

The risk of side effects with GLP-1 therapies varies widely among patients, yet treatment decisions often overlook this variability. Why do some patients tolerate GLP-1 receptor agonists with ease while others discontinue early? Much like how individuals respond differently to diet or exercise, medication tolerance is influenced by a mix …

The rise of newer incretin-based therapies is changing how clinicians think about diabetes care. But are GLP-1 receptor agonists already being challenged by this next wave of incretin therapy? While these medications have transformed treatment in recent years, newer multi-agonist therapies are gaining attention. As a result, healthcare providers are …

What does success really look like with GLP-1 therapy in 2026? Is it simply lowering A1C, or are clinicians now aiming for something more sustainable like remission or long-term maintenance? As GLP-1 receptor agonists continue to transform diabetes care, the conversation is shifting beyond short-term outcomes. Today, defining clear and …

GLP-1 dose escalation is quickly becoming a central topic in diabetes care, especially as higher dosing strategies gain traction. But are we truly entering a high-dose era, or simply refining how we use these powerful agents? As clinicians face patients who plateau on standard regimens, the question becomes not just …